Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-03-01
2005-03-01
Raymond, Richard L. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S254040, C544S367000, C544S369000
Reexamination Certificate
active
06861433
ABSTRACT:
The present invention provides compounds of the formula:compositions comprising such compounds, and methods for using the same.
REFERENCES:
patent: 5652238 (1997-07-01), Brickner et al.
patent: 5910504 (1999-06-01), Hutchinson
patent: WO 9309103 (1993-05-01), None
patent: WO 9514684 (1995-06-01), None
patent: WO 9941244 (1999-08-01), None
patent: WO 0010566 (2000-03-01), None
patent: WO 0194342 (2001-12-01), None
Matassova, N.B., et al., “Ribosomal RNA is the target for oxazolidinones, a novel class of translation inhibitors,”RNA, 1999, 5, 939-946.
Porse, B.T., et al., “direct crosslinking of the antitumor antibiotic sparsomycin, and its derivatives, to A2602 in the peptidyl transferase center of 23S-like rRNA within ribosome-tRNA complexes,”Proc. Natl. Acad. Sci. USA, 1999, 96, 9003-9008.
Gadwood Robert C.
Thomasco Lisa Marie
Pharmacia & Upjohn Company
Raymond Richard L.
Yang Lucy X.
LandOfFree
Oxazolidinone photoaffinity probes does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Oxazolidinone photoaffinity probes, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Oxazolidinone photoaffinity probes will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3412606